FR2593519B1 - VACCINE AGAINST ACQUIRED AND INTERMEDIATE IMMUNODEFICITARY SYNDROME FOR THE PREPARATION OF THIS VACCINE - Google Patents

VACCINE AGAINST ACQUIRED AND INTERMEDIATE IMMUNODEFICITARY SYNDROME FOR THE PREPARATION OF THIS VACCINE

Info

Publication number
FR2593519B1
FR2593519B1 FR8605073A FR8605073A FR2593519B1 FR 2593519 B1 FR2593519 B1 FR 2593519B1 FR 8605073 A FR8605073 A FR 8605073A FR 8605073 A FR8605073 A FR 8605073A FR 2593519 B1 FR2593519 B1 FR 2593519B1
Authority
FR
France
Prior art keywords
vaccine
immunodeficitary
syndrome
preparation
against acquired
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR8605073A
Other languages
French (fr)
Other versions
FR2593519A1 (en
Inventor
Hu Et Anthony F. Purchio Shiu-Lok
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncogen LP
Original Assignee
Oncogen LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen LP filed Critical Oncogen LP
Publication of FR2593519A1 publication Critical patent/FR2593519A1/en
Application granted granted Critical
Publication of FR2593519B1 publication Critical patent/FR2593519B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
FR8605073A 1985-09-25 1986-04-09 VACCINE AGAINST ACQUIRED AND INTERMEDIATE IMMUNODEFICITARY SYNDROME FOR THE PREPARATION OF THIS VACCINE Expired - Fee Related FR2593519B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77990985A 1985-09-25 1985-09-25
US84298486A 1986-03-27 1986-03-27

Publications (2)

Publication Number Publication Date
FR2593519A1 FR2593519A1 (en) 1987-07-31
FR2593519B1 true FR2593519B1 (en) 1994-01-07

Family

ID=27119638

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8605073A Expired - Fee Related FR2593519B1 (en) 1985-09-25 1986-04-09 VACCINE AGAINST ACQUIRED AND INTERMEDIATE IMMUNODEFICITARY SYNDROME FOR THE PREPARATION OF THIS VACCINE

Country Status (4)

Country Link
BE (1) BE905492A (en)
FR (1) FR2593519B1 (en)
LU (1) LU86608A1 (en)
PH (1) PH26855A (en)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE78293T1 (en) * 1983-05-27 1992-08-15 Texas A & M Univ Sys METHOD OF GENERATING A RECOMBINANT BACULOVIRUS EXPRESSION VECTOR.
IL76082A (en) * 1984-08-22 1991-07-18 Us Health Molecular clones of the genome of htlv-iii and a process for the preparation thereof
US9328391B1 (en) * 1984-08-22 2016-05-03 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cloning and expression of HIV-1 DNA
GB8501473D0 (en) * 1985-01-21 1985-02-20 Pasteur Institut Cloned dna sequences
EP0201540B2 (en) * 1984-10-18 2001-10-31 Institut Pasteur Envelope antigens of lymphadenopathy associated virus and their applications
CA1341423C (en) * 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
DE3588134T2 (en) * 1984-12-24 1997-03-20 Genentech Inc Fusion of AIDS-related polypeptides
US4774175A (en) * 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
GR860915B (en) * 1985-04-08 1986-07-11 Genetic Systems Corp Expression and diagnostic use of gag encoded peptides which are immunologically reactive with antibodies to lav
DK171119B1 (en) * 1985-04-19 1996-06-17 Hoffmann La Roche AIDS virus envelope protein, expression vector carrying the envelope protein, transformants transformed with the expression vector, method of producing the virus envelope protein, method of detecting AIDS antibodies, method of determining AIDS virus, vaccine against AIDS, antibodies against the virus envelope protein and use of it to prepare a vaccine and for testing
FR2586427B1 (en) * 1985-08-20 1988-12-09 Pasteur Institut NUCLEOTIDE AND POLYPEPTIDE SEQUENCES FROM VISNA VIRUS AND THEIR APPLICATION TO DIAGNOSTIC TESTS AND THE PRODUCTION OF IMMUNOGENIC COMPOSITIONS

Also Published As

Publication number Publication date
FR2593519A1 (en) 1987-07-31
BE905492A (en) 1987-03-25
LU86608A1 (en) 1988-04-05
PH26855A (en) 1992-11-16

Similar Documents

Publication Publication Date Title
DK708088A (en) PHARMACEUTICAL PREPARATION WITH EXTENDED RELEASE TIME
IT1199838B (en) METHODS FOR THE PREPARATION OF DRESSINGS
DK153787A (en) SLOW-DELIVERY MEDICINAL PRODUCTS
DK16487D0 (en) VACCINES FOR ORAL ADMINISTRATION
DK410787A (en) ORAL THERAPEUTIC SYSTEM WITH SYSTEMIC EFFECT
DK52787D0 (en) PHARMACEUTICAL PREPARATION WITH PROTRAACTED EFFECTS AND PROCEDURES FOR PREPARING IT
NO872551D0 (en) PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS
DK537685A (en) PROCEDURE FOR THE PREPARATION OF ISOSILYBIN-FREE SILIBININ AND MEDICINAL PRODUCTS CONTAINING THEREOF
NO862141L (en) PROCEDURE FOR THE PREPARATION OF ACTIVE CINNOLINE DERIVATIVES
DK226488A (en) USE OF ACE INHIBITORS FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS
NO874200D0 (en) PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS
IT1200400B (en) PROCEDURE FOR THE PREPARATION OF 2-ALCHIL CICLOPENT-2-ENONI
IT1200594B (en) PROCEDURE FOR THE PREPARATION OF ALFA-OMEGA-ALOPERFLUOROCARBURI
NO873423D0 (en) PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS
NO872233D0 (en) PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS
NO875359L (en) PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS
FI93423C (en) Procedure for the preparation of vaccine
FR2593519B1 (en) VACCINE AGAINST ACQUIRED AND INTERMEDIATE IMMUNODEFICITARY SYNDROME FOR THE PREPARATION OF THIS VACCINE
TR24449A (en) USE AS THE PROCEDURE V AND FUNGUSID FOR THE PREPARATION OF TIYAZINOL TUEREVLER
IT1190358B (en) PROCEDURE FOR THE PREPARATION OF L-CARNITINA
IT1191806B (en) PROCEDURE FOR THE PREPARATION OF 2-BROMO-ALFA-ERGOCRIPTINA
DK701588D0 (en) N-HYDROXY-5-PHENYL-2-FURANCARBOXIMIDAMIDES AND ITS USE FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS
DK499986A (en) PHARMACEUTICAL PREPARATION WITH ANTIBACTERIAL EFFECT
IT1202567B (en) PREPARATION OF PHARMACEUTICAL INJECTABLE AMOXICILLIN
IT8848410A0 (en) PROCEDURE FOR THE PREPARATION OF SHOTTERED CONCRETE

Legal Events

Date Code Title Description
ST Notification of lapse